-
公开(公告)号：US11673953B2
公开(公告)日：2023-06-13
申请号：US16802822
申请日：2020-02-27
Applicant: ALLOGENE THERAPEUTICS, INC. , PFIZER INC.
Inventor： Yi Zhang , Thomas John Van Blarcom , Siler Panowski , Silvia K. Tacheva-Grigorova , Barbra Johnson Sasu
CPC classification number: C07K16/2809 , A61P35/00 , C07K16/2887 , C12N15/63 , A61K2039/505 , C07K2317/24 , C07K2317/565 , C07K2317/622 , C07K2319/70
Abstract: Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using DLL3-specific CARs, and immune cells comprising DLL3-specific CARs.
-
公开(公告)号：US12215347B2
公开(公告)日：2025-02-04
申请号：US17381693
申请日：2021-07-21
Applicant: Allogene Therapeutics, Inc.
Inventor： Michael Thomas Bethune , Yi Zhang , Thomas John Van Blarcom , Siler Panowski , Barbra Johnson Sasu
IPC: C12N5/0783 , A61K39/00 , C07K14/725 , C12N15/86
Abstract: Provided herein are recombinant antigen receptors, for example chimeric antigen receptors (CARs), that comprise modified cytoplasmic domains that provide improved signalling and thereby provide improved performance and safety. Also provided are polynucleotides encoding the recombinant antigen receptors, vectors comprising the polynucleotides, and engineered immune cells comprising the vectors and/or polynucleotides. The invention further provides methods for engineering immune cells to express the recombinant antigen receptors. Improved recombinant antigen receptor signalling is also provided by co-expressing a first recombinant antigen receptor and a second recombinant antigen receptor or co-expressing a recombinant antigen receptor and a protein involved in transducing the signal from the activated recombinant antigen receptor. Also provided are methods of treating a variety of conditions, including, but not limited to, blood cancers and cancers characterized by solid tumors, by administering the engineered cells to patients suffering from such a condition.
-
公开(公告)号：US12036243B2
公开(公告)日：2024-07-16
申请号：US17183689
申请日：2021-02-24
Applicant: Allogene Therapeutics, Inc.
Inventor： Regina Junhui Lin , Siler Panowski , Cesar Adolfo Sommer , Thomas John Van Blarcom , Barbra Johnson Sasu , Arun Balakumaran
IPC: A61K35/17 , A61P35/00 , C07K14/715 , C07K16/28 , C12N15/86
CPC classification number: A61K35/17 , A61P35/00 , C07K14/7151 , C07K16/2878 , C12N15/86
Abstract: Provided here are engineered immune cells that comprise a constitutively active chimeric cytokine receptor (CACCR) and a B-cell maturation antigen (BCMA) specific chimeric antigen receptor (CAR). Also provided herein are engineered immune cells that comprise one or more nucleic acids e.g. a bicistronic vector such as a viral vector that encode the CACCRs and BCMA CARs and engineered immune cells e.g. engineered autologous or allogeneic T cells that express both CACCRs and BCMA CARs from the nucleic acids. When present on chimeric antigen receptor (CAR)-bearing engineered immune cells, the CACCRs allow for increased immune cell activation, proliferation, persistence, and/or potency. Further provided herein are methods of making and using the engineered immune cells described herein, such as methods of treating a disease or condition by administering at least one appropriate dose of the cells to a patient suffering from the condition.
-
公开(公告)号：US11786553B2
公开(公告)日：2023-10-17
申请号：US16804545
申请日：2020-02-28
Applicant: Allogene Therapeutics, Inc.
Inventor： Regina Junhui Lin , Thomas John Van Blarcom , Siler Panowski , Barbra Johnson Sasu
CPC classification number: A61K35/17 , C07K14/7155 , C07K16/2818 , C07K16/30 , C12N15/67 , A61K38/00 , C07K2319/03 , C07K2319/33 , C07K2319/74
Abstract: Provided herein are PD-1 chimeric cytokine receptors. When present on chimeric antigen receptor (CAR)-bearing immune cells, such receptors allow for increased immune cell activation, proliferation, persistence, and/or potency, when engaged with PD-1 ligands or activation with an anti-PD-1 antibody. Also provided are methods of making and using the chimeric cytokine receptors described herein.
-
公开(公告)号：US12043655B2
公开(公告)日：2024-07-23
申请号：US16804917
申请日：2020-02-28
Applicant: Allogene Therapeutics, Inc.
Inventor： Regina Junhui Lin , Thomas John Van Blarcom , Siler Panowski , Barbra Johnson Sasu
IPC: C07K14/715 , A61K35/17 , A61K39/00 , A61P35/00 , C07K16/40 , C12N5/0783 , C12N7/00 , C12N15/86
CPC classification number: C07K14/715 , A61K35/17 , A61P35/00 , C07K16/40 , C12N5/0636 , C12N7/00 , C12N15/86 , C07K2317/24 , C07K2317/73 , C07K2319/02 , C07K2319/03 , C07K2319/30 , C07K2319/33 , C12N2740/15043
Abstract: Provided herein are constitutively active chimeric cytokine receptors (CACCRs). When present on chimeric antigen receptor (CAR)-bearing immune cells, such CACCRs allow for increased immune cell activation, proliferation, persistence, and/or potency. Also provided are methods of making and using the CACCRs described herein.
-
Patent Agency Ranking
公开(公告)号：US20190233528A1
公开(公告)日：2019-08-01
申请号：US16264371
申请日：2019-01-31
Applicant: Pfizer Inc.
Inventor： Surabhi Srivatsa Srinivasan , Niranjana Aditi Nagarajan , Siler Panowski , Yoon Park , Tao Sai , Barbra Johnson SASU , Thomas John Van Blarcom , Mathilde Brunnhilde Dusseaux , Roman Ariel Galetto
IPC: C07K16/28 , C07K14/725 , A61K39/00 , A61P35/02 , A61P35/04
CPC classification number: C07K16/2875 , A61K39/001129 , A61K39/001138 , A61K2039/5156 , A61P35/02 , A61P35/04 , C07K14/7051 , C07K2317/622 , C07K2317/92 , C07K2317/94 , C07K2319/02 , C07K2319/03 , C07K2319/33
Abstract: The disclosure provides CARs (CARs) that specifically bind to CD70. The disclosure further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The disclosure further relates to therapeutic methods for use of these CARs and engineered immune cells comprising these CARs for the treatment of a condition associated with malignant cells expressing CD70 (e.g., cancer).
-
公开(公告)号：US20230002498A1
公开(公告)日：2023-01-05
申请号：US17830324
申请日：2022-06-01
Applicant: Pfizer Inc.
Inventor： Siler Panowski , Tao Sai , Barbra Johnson Sasu , Surabhi Srivatsa Srinivasan , Thomas John Van Blarcom
Abstract: The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.
-
公开(公告)号：US12152081B2
公开(公告)日：2024-11-26
申请号：US17843616
申请日：2022-06-17
Applicant: Pfizer Inc.
Inventor： Surabhi Srivatsa Srinivasan , Niranjana Nagarajan , Siler Panowski , Yoon Park , Tao Sai , Barbra Sasu , Thomas Van Blarcom , Mathilde Dusseaux , Roman Galetto
IPC: C07K16/28 , A61K39/00 , A61P35/02 , A61P35/04 , C07K14/725
Abstract: The disclosure provides CARs (CARs) that specifically bind to CD70. The disclosure further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The disclosure further relates to therapeutic methods for use of these CARs and engineered immune cells comprising these CARs for the treatment of a condition associated with malignant cells expressing CD70 (e.g., cancer).
-
公开(公告)号：US11987634B2
公开(公告)日：2024-05-21
申请号：US17830324
申请日：2022-06-01
Applicant: Pfizer Inc.
Inventor： Siler Panowski , Tao Sai , Barbra Johnson Sasu , Surabhi Srivatsa Srinivasan , Thomas John Van Blarcom
CPC classification number: C07K16/2875 , A61P35/00 , C07K16/2809 , A61K2039/505 , C07K2317/31 , C07K2317/526 , C07K2317/53 , C07K2317/565 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92
Abstract: The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.
-
公开(公告)号：US11377500B2
公开(公告)日：2022-07-05
申请号：US16264485
申请日：2019-01-31
Applicant: Pfizer Inc.
Inventor： Siler Panowski , Tao Sai , Barbra Johnson Sasu , Surabhi Srivatsa Srinivasan , Thomas John Van Blarcom
Abstract: The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.017 seconds)
